Skip to main content

Peer Review reports

From: Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study

Original Submission
26 Sep 2021 Submitted Original manuscript
17 Dec 2021 Reviewed Reviewer Report
21 Jan 2022 Reviewed Reviewer Report - Yuko Oya
10 Feb 2022 Author responded Author comments - Ming Chen
14 Feb 2022 Author responded Author comments - Ming Chen
Resubmission - Version 2
10 Feb 2022 Submitted Manuscript version 2
24 Feb 2022 Reviewed Reviewer Report
7 Mar 2022 Reviewed Reviewer Report - Yuko Oya
19 Mar 2022 Author responded Author comments - Ming Chen
Resubmission - Version 3
19 Mar 2022 Submitted Manuscript version 3
20 Apr 2022 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
3 May 2022 Editorially accepted
6 May 2022 Article published 10.1186/s12890-022-01981-5

You can find further information about peer review here.

Back to article page